In the original article, there were errors in the calculation of standard deviation and *P* values shown in Figure [5](#feb412797-fig-0005){ref-type="fig"} and in the chi square test for gender in Table [1](#feb412797-tbl-0001){ref-type="table"}. Corrected versions of Figure [5](#feb412797-fig-0005){ref-type="fig"} and Table [1](#feb412797-tbl-0001){ref-type="table"} are provided here. This does not affect the conclusions of the paper.

![SOX6 inhibits the G1/S transition. (A) Flow cytometry was performed to assess the cell cycle. The percentage of cells in G1 phase was higher in SOX6‐A549 and SOX6‐HCC827 cells compared with those of the respective control cells. (B) Histogram of cell ratio at each phase in the stable SOX6‐expressing clones (SOX6‐A549 and SOX6‐HCC827) compared with the controls (Vec‐A549 and Vec‐HCC827). *n* = 3. Student's *t*‐test was used. Error bars represent SD. \*\**P* \< 0.05, \*\*\**P* \< 0.01.](FEB4-10-484-g001){#feb412797-fig-0005}

###### 

Analysis of the relationship between patients\' clinicopathological characteristics and SOX6 expression.

  Clinicopathological features   Case, *n*   sox6 expression, *n*(%)   *χ* ^2^     *P*‐value   
  ------------------------------ ----------- ------------------------- ----------- ----------- ---------
  Tumor cell differentiation                                                                   
  Well                           52          19 (36.6)                 33 (63.4)   21.5606     0.000\*
  Moderate                       50          34 (68.0)                 16 (32.0)               
  Poor                           43          35 (81.3)                 8 (18.7)                
  Gender                                                                                       
  Male                           71          44 (62.0)                 27 (38.0)   0.096       0.757
  Female                         74          44 (60.0)                 30 (40.0)               
  Age, y                                                                                       
  ≤ 60                           77          46 (59.7)                 31 (40.3)   0.062       0.803
  \> 60                          68          42 (61.8)                 26 (38.2)               
  Lymph nodes metastasis (N)                                                                   
  N0                             93          50 (53.7)                 43 (46.3)   5.2146      0.022\*
  N1                             52          38 (73.1)                 14 (26.9)               
  TNM stage                                                                                    
  I                              88          48 (54.5)                 40 (45.5)   4.2988      0.117
  II                             35          23 (65.7)                 12 (34.3)               
  III                            22          17 (77.3)                 5 (22.7)                

Down‐regulation: sections with overall scores of 0--3; ^b^Normal: sections with overall scores ≥ 4; \**P *\< 0.05.
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